{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+control+group&page=11", "query": { "intervention": "matched control group", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 2810, "total_pages": 281, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+control+group&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=matched+control+group&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T00:43:37.093Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03103087", "title": "LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 382, "start_date": "2017-06-14", "completion_date": "2020-09-16", "has_results": true, "last_update_posted_date": "2022-04-20", "last_synced_at": "2026-11-01T00:43:37.093Z", "location_count": 89, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Canoga Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03103087" }, { "nct_id": "NCT02188290", "title": "Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Kiadis Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 178, "start_date": "2014-09", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2015-10-06", "last_synced_at": "2026-11-01T00:43:37.093Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188290" }, { "nct_id": "NCT04899271", "title": "A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "New-onset Type 1 Diabetes" ], "interventions": [ { "name": "Ladarixin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dompé Farmaceutici S.p.A", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 25, "start_date": "2020-12-14", "completion_date": "2023-10-11", "has_results": true, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-11-01T00:43:37.093Z", "location_count": 2, "location_summary": "Aurora, Colorado • Atlanta, Georgia", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04899271" }, { "nct_id": "NCT04863781", "title": "Mobile Stress Management Program for African American Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Psychological Stress" ], "interventions": [ { "name": "Mobile cognitive-behavioral stress management intervention", "type": "BEHAVIORAL" }, { "name": "Control", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "ISA Associates, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 139, "start_date": "2023-03-31", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-11-01T00:43:37.093Z", "location_count": 1, "location_summary": "Alexandria, Virginia", "locations": [ { "city": "Alexandria", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04863781" }, { "nct_id": "NCT03937219", "title": "Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Cabozantinib-matched placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 855, "start_date": "2019-06-25", "completion_date": "2027-01-31", "has_results": true, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-01T00:43:37.093Z", "location_count": 30, "location_summary": "La Jolla, California • Orange, California • Boca Raton, Florida + 23 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03937219" }, { "nct_id": "NCT01843036", "title": "Durham Connects RCT Evaluation II", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Unspecified Child Maltreatment, Suspected", "Unspecified Child Maltreatment, Confirmed" ], "interventions": [ { "name": "Durham Connects", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "6 Months", "sex": "ALL", "summary": "Up to 6 Months" }, "enrollment_count": 1650, "start_date": "2014-01", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-11-01T00:43:37.093Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01843036" }, { "nct_id": "NCT06300892", "title": "Surgical Site Infections and the Microbiome: Understanding the Pathogenesis of Surgical Site Infections", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Open GI Surgery" ], "interventions": [ { "name": "No intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2024-04-01", "completion_date": "2026-06-15", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-01T00:43:37.093Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06300892" }, { "nct_id": "NCT03896711", "title": "MEMORI Corps: Activity-based Companion Care for Dementia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease", "Dementia" ], "interventions": [ { "name": "MEMORI Corps program", "type": "BEHAVIORAL" }, { "name": "Augmented Waitlist Control", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "115 Years", "sex": "ALL", "summary": "18 Years to 115 Years" }, "enrollment_count": 175, "start_date": "2022-03-01", "completion_date": "2025-05-31", "has_results": true, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-11-01T00:43:37.093Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03896711" }, { "nct_id": "NCT05452239", "title": "A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Migraine", "Medication Overuse Headache" ], "interventions": [ { "name": "Eptinezumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 608, "start_date": "2022-07-01", "completion_date": "2025-03-13", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-11-01T00:43:37.093Z", "location_count": 6, "location_summary": "Winter Haven, Florida • Marrero, Louisiana • Springfield, Missouri + 3 more", "locations": [ { "city": "Winter Haven", "state": "Florida" }, { "city": "Marrero", "state": "Louisiana" }, { "city": "Springfield", "state": "Missouri" }, { "city": "Amherst", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05452239" }, { "nct_id": "NCT06451757", "title": "KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mitochondrial Diseases", "Maternally Inherited Diabetes and Deafness (MIDD)", "Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)", "Mitochondrial DNA tRNALeu(UUR) m.3243A